Cargando…

SAT-557 Functional Thyrotropin Receptor Antibodies Confirm a Novel Graves' Disease Animal Model

Background / Objectives: A novel long-term animal model for human Graves’ disease (GD) was recently established in mice (Endocrinology 2015; 156: 1577-1589) using nine immunizations with recombinant adenovirus (Ad) expressing the extracellular A-subunit of the human thyrotropin receptor (TSHR) over...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diana, Tanja, Ungerer, Martin, Reimann, Andreas, Faßbender, Julia, Kanitz, Michael, Kahaly, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Thyroid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552466/ http://dx.doi.org/10.1210/js.2019-SAT-557

Ejemplares similares

MON-583 Functional Thyrotropin Receptor Antibodies in Pregnant Women with Thyroid Autoimmunity
por: Diana, Tanja, et al.
Publicado: (2019)

OR18-03 Functional TSH Receptor Antibodies Are a Biomarker for Graves’ Disease - a Prospective Trial
por: Kahaly, George Jean, et al.
Publicado: (2020)

SAT-429 Systemic Safety Analysis of Mycophenolate in Graves’ Orbitopathy
por: Lee, Alan C H, et al.
Publicado: (2020)

Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease
por: Kahaly, George J, et al.
Publicado: (2019)

SAT557 Unexpected Whole Body Scan Finding
por: Gastelum, Alheli Arce, et al.
Publicado: (2023)

SUN-557 Thymic Hyperplasia in Graves' Disease: A Case Series
por: Voss, Michael, et al.
Publicado: (2019)

SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
por: Kahaly, George, et al.
Publicado: (2019)

Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves’ Orbitopathy
por: George, Augustine, et al.
Publicado: (2021)

FRI537 Thyrotropin Receptor Blocking Antibodies - A Multicenter, 4-Assay Comparison
por: George, Augustine, et al.
Publicado: (2023)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2021)

OR26-01 A Novel Small Molecule Thyrotropin Receptor Antagonist
por: Kahaly, George Jean, et al.
Publicado: (2023)

FRI557 Don’t Forget The Incidental Thyroid Nodule In Graves’ Disease. A Case of Marine-Lenhart Syndrome
por: Andino-Lebrón, Katira Nicole, et al.
Publicado: (2023)

FRI540 A Novel, Rapid, Sensitive Bioassay For Thyrotropin Receptor Stimulatory Antibodies Improves Diagnosis & Management Of Autoimmune Thyroid Disease
por: Jean Kahaly, George, et al.
Publicado: (2023)

SAT-582 Autoimmune Hepatitis Presenting with Graves Disease
por: Coy, Andres, et al.
Publicado: (2019)

MON-593 Thyrotropin Receptor Stimulating Immunoglobulin: Clinical Utility in Graves' Disease Diagnosis
por: Marques, Bernardo, et al.
Publicado: (2019)

SAT-476 Alemtuzumab Induced Graves Disease
por: Caputi, Rafael C, et al.
Publicado: (2020)

SAT489 Grave’s Disease Secondary To Alemtuzumabuse
por: Gong, Michael Shifeng, et al.
Publicado: (2023)

Thyrotropin Receptor Blocking Antibodies
por: Diana, Tanja, et al.
Publicado: (2018)

SAT-603 Graves' Disease and an Anterior Mediastinal Mass
por: Robbins, D'lorah, et al.
Publicado: (2019)

SAT-592 Amiodarone-Induced Cure Of Graves' Disease
por: Sharma, Eliza, et al.
Publicado: (2019)

SAT-605 Immune Thrombocytopenic Purpura in Graves' disease
por: Sajja, Puspalatha, et al.
Publicado: (2019)

OR19-6 A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, Successfully Treats Graves’ Hyperthyroidism
por: Kahaly, George, et al.
Publicado: (2019)

SAT-428 Sex-Specific Risk Gene of Graves’ Disease
por: Zhao, Shuangxia, et al.
Publicado: (2020)

SAT-459 A Grave Complication: Pulmonary Arterial Hypertension
por: Butt, Wajeeha Saeed, et al.
Publicado: (2020)

SAT-498 Graves’-Associated Takotsubo Cardiomyopathy: An Uncommon Condition
por: Mortensen, Michael, et al.
Publicado: (2020)

SAT462 TSI Versus TRAb In The Diagnosis Of Grave’s Disease
por: Ibrahim, Katherine, et al.
Publicado: (2023)

SAT-443 Impact of Fasting on Plasma Thyrotropin in Hypothyroid Patients Taking Levothyroxine During Ramadan (IFT-R Study)
por: El-Kaissi, Samer, et al.
Publicado: (2020)

SAT-588 Unique Presentation of Postpartum Thyroiditis with Features of Graves' Disease
por: Havranova, Jana, et al.
Publicado: (2019)

SAT488 Wolff-Chaikoff’s Revenge: There-and-Back Again Graves Thyrotoxicosis
por: Akofu, Anota, et al.
Publicado: (2023)

SAT490 Graves’ Disease In Remission Aggravated By Himalayan Salt Consumption
por: Shakir, Mohamed K M, et al.
Publicado: (2023)

MON-557 Resource Utilization in the Surveillance of Differentiated Thyroid Cancer: The Impact of Patient Preferences
por: Evron, Josh, et al.
Publicado: (2019)

SAT-581 Graves' Disease and Hashimoto's Thyroiditis: Two Ends of a Spectrum
por: Morselli, Lisa, et al.
Publicado: (2019)

SAT-463 Thyrotoxicosis from Nivolumab in a Patient with Preexisting Graves’ Disease
por: Polavarapu, Preethi, et al.
Publicado: (2020)

SAT-413 Does Dipeptidyl Peptidase-4 Inhibitor Exacerbate Graves’ Disease?
por: Sekizaki, Tomonori, et al.
Publicado: (2020)

SAT-471 A Rare Case of Pretibial Myxedema Preceding Graves’ Hyperthyroidism
por: Bao, Ginny W, et al.
Publicado: (2020)

SAT-415 Clinical Performance of Thyroid-Stimulating Immunoglobulin for Graves′ Disease Diagnosis
por: Marui, Suemi, et al.
Publicado: (2020)

SAT-497 Conversion of Hashimoto’s Thyroiditis to Grave’s Disease: A Case Report
por: Wahedi, Tayba S, et al.
Publicado: (2020)

SAT-584 Pembrolizumab-Related Graves' Disease: A Rare Adverse Effect of an Anti-PD-1 Antibody Cancer Immunotherapy
por: Narayen, Garima, et al.
Publicado: (2019)

SAT459 Teprotumumab Pooled Efficacy From The European Study Sites Participating In The Phase 2, OPTIC (Phase 3) And OPTIC-X Pivotal Trials
por: Kahaly, George J, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_51lrbrhd3v00ea03b913aejpcv